Glutathione peroxidase and CT scan abnormalities in schizophrenia

Buckman, Trent D.; Kling, Arthur; Eiduson, Samuel; Sutphin, Mary S.; Steinberg, Alan M.

doi:10.1016/0006-3223(87)90069-2

Cited by 64 publications

(24 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Others have reported unchanged levels for these three enzymes (Srivastava et al, 2001), or altered concentrations of individual enzymes (Abdalla et al, 1986;Akyol et al, 2002;Altuntas et al, 2000;DietrichMuszalska et al, 2005;Herken et al, 2001;Kuloglu et al, 2002c ;Zhang et al, 2006a). A strong negative correlation between blood GSH-Px and structural measures of brain atrophy was also reported by an early study (Buckman et al, 1987). Furthermore, some studies have differentiated enzymatic changes among the schizophrenia subtypes (Herken et al, 2001;Zhang et al, 2006a), and one study showed a linear correlation between antioxidant enzyme levels and positive symptom severity .…”

Section: Assays Of Oxidants and Antioxidantsmentioning

confidence: 89%

Oxidative stress in psychiatric disorders: evidence base and therapeutic implications

Berk

Dean

et al. 2008

Int. J. Neuropsychopharm.

860

569

View full text Add to dashboard Cite

Oxidative stress has been implicated in the pathogenesis of diverse disease states, and may be a common pathogenic mechanism underlying many major psychiatric disorders, as the brain has comparatively greater vulnerability to oxidative damage. This review aims to examine the current evidence for the role of oxidative stress in psychiatric disorders, and its academic and clinical implications. A literature search was conducted using the Medline, Pubmed, PsycINFO, CINAHL PLUS, BIOSIS Previews, and Cochrane databases, with a time-frame extending to September 2007. The broadest data for oxidative stress mechanisms have been derived from studies conducted in schizophrenia, where evidence is available from different areas of oxidative research, including oxidative marker assays, psychopharmacology studies, and clinical trials of antioxidants. For bipolar disorder and depression, a solid foundation for oxidative stress hypotheses has been provided by biochemical, genetic, pharmacological, preclinical therapeutic studies and one clinical trial. Oxidative pathophysiology in anxiety disorders is strongly supported by animal models, and also by human biochemical data. Pilot studies have suggested efficacy of N-acetylcysteine in cocaine dependence, while early evidence is accumulating for oxidative mechanisms in autism and attention deficit hyperactivity disorder. In conclusion, multi-dimensional data support the role of oxidative stress in diverse psychiatric disorders. These data not only suggest that oxidative mechanisms may form unifying common pathogenic pathways in psychiatric disorders, but also introduce new targets for the development of therapeutic interventions.

show abstract

Section: Assays Of Oxidants and Antioxidantsmentioning

confidence: 89%

Oxidative stress in psychiatric disorders: evidence base and therapeutic implications

Berk

Dean

et al. 2008

Int. J. Neuropsychopharm.

860

569

View full text Add to dashboard Cite

show abstract

“…Still, there is evidence that peripheral blood cells share more than 80% of the transcriptome with brain tissue and that many biological processes are comparable [36,56]. It was also documented that brain atrophy is related to signs of pro-oxidative as well as pro-inflammatory states in peripheral blood of patients with psychiatric disorders [57,58]. Furthermore, our results of increased levels of CuZnSOD are in concordance with one previous study that also showed increased concentrations of CuZnSOD in the prefrontal cortex and the same trend in the hippocampus of patients with MDD [34].…”

Section: Discussionmentioning

confidence: 99%

Lymphocyte Levels of Redox-Sensitive Transcription Factors and Antioxidative Enzymes as Indicators of Pro-Oxidative State in Depressive Patients

Lukić¹,

Mitić²,

Djordjević³

et al. 2014

Neuropsychobiology

View full text Add to dashboard Cite

Background: Oxidative stress is reliably observed in major depressive disorder (MDD). However, molecular data on the principal cellular redox-sensitive transcriptional factors and the levels of their downstream-regulated antioxidant enzymes in MDD are scarce. Methods: In the peripheral blood mononuclear cells (PBMC) of subjects with a current episode of MDD (n = 30) and healthy controls (n = 35), we investigated alterations in the levels of redox-sensing nuclear factor (erythroid-derived 2)-like 2 (Nrf2) protein, its inhibitor Keap1, and nuclear factor-κB (NF-κB), along with their cognate downstream effectors, the antioxidant enzymes (AOEs): manganese and copper zinc superoxide dismutase (MnSOD and CuZnSOD, respectively), catalase (CAT), glutathione peroxidase (GPx) and glutathione reductase (GLR). Results: MDD subjects exhibited higher levels of Nrf2 and its regulator Keap1, as well as NF-κB in the cytoplasm of PBMC compared to controls. This state was further reflected by increased levels of MnSOD, CuZnSOD and CAT proteins and by the lack of correlation between MnSOD and CAT, which could indicate impaired oxidative detoxification capacity in MDD patients. Moreover, increased levels of MnSOD, CuZnSOD and CAT in MDD patients positively correlated with levels of Nrf2, while increased levels of SODs were also positively related to NF-κB. There were no differences regarding the levels of GPx and GLR proteins, but the ratio of GLR/GPx was reduced, suggesting diminished capacity of GPx in antioxidative defence in PBMC of MDD subjects. Conclusion: These data provide evidence that MDD is characterized by up-regulation of redox-sensitive transcriptional factors (Nrf2 and NF-κB) and AOEs (MnSOD, CuZnSOD and CAT), indicating pro-oxidative state in the PBMC of MDD patients.

show abstract

“…Increased levels of plasma SOD activities were reported in chronic schizophrenic patients who were put on antipsychotic medication, and SOD activities were negatively correlated with positive symptoms of schizophrenics (Ranjekar et al, 2003). Levels of other antioxidants, including glutathione peroxidase (GSH-Px), also have been implicated (Abdalla et al, 1986;Stoklasová et al, 1986;Buckman et al, 1987;Altuntas et al, 2000). It has been suggested that low GSH-Px is a contributing factor to structural brain abnormalities (Buckman et al, 1990;Yao and Reddy, 2011).…”

Section: Oxidative Stress and Neuropsychiatric Disordersmentioning

confidence: 99%